Patient-reported outcomes and visual acuity after 12 months of anti-VEGF-treatment for sight-threatening diabetic macular edema in a real world setting

This study was an evaluation, at 12 months follow-up, of anti VEGF treatment for diabetic macular edema conducted in a real world setting.  To examine objective visual acuity measured with ETDRS, retinal thickness (OCT), patient reported outcome and describe levels of glycated hemoglobin and its association with the effects on visual acuity in patients treated with anti-VEGF for visual impairment … [Read more...]

Pharma News: Bayer, Johns Hopkins partner to develop new ophthalmic therapies

Bayer HealthCare has entered into a five-year collaboration agreement with The Johns Hopkins University in Baltimore, US, for the discovery and development of new therapies in ophthalmology targeting retinal diseases.  Both the parties will jointly conduct research activities evaluating new targets and disease mechanisms, drug delivery technologies, and biomarkers for back-of-the-eye diseases with … [Read more...]

Preclinical Ophthalmic Contract Research